Natco Pharma is an Indian multinational
pharmaceutical company based in
Hyderabad. The company manufactures finished dosage formulations
active pharmaceutical ingredients and Agro chemical products.[5] It is a major producer of branded
oncology medicines[6] cardiology, diabetology and other pharma specialty drugs.[7] The company specialises in producing complex medicines at affordable prices.[8][9] NATCO is a science driven company and focuses on limited competition molecules in the US.
[10][11]
History
NATCO Pharma was founded in the year 1981 by V C Nannapaneni
In 1983 operations commenced at manufacturing facility at Nagarjunasagar, Telangana
In 1986 Chemical division commenced at Mekaguda, Telangana
In 2008, NATCO Pharma filed its first paragraph IV filing in the US with the USFDA, [12]
In 2012, NATCO Pharma obtained
compulsory license to produce a cheaper and generic version of
Bayer's anti-cancer medication
Nexavar.[7]
In 2016, NATCO Pharma launched the first
Tamiflu capsule in the US market.[13]
In 2019, NATCO Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in
Nellore district,
Andhra Pradesh.[14]
In 2022 Crop Health Sciences division launched Chlorantraniliprole (CTPR) based products.
NATCO launched the first generic version of Revlimid in the US market
For the financial Year 2024, NATCO recorded its highest ever revenue, Earnings Before Interests Tax Depreciation and Amortization and profit after tax.